ArticleResearch and reports in urology2026
A Retrospective Analysis of Testicular Cancer (2007-2025): A Single Institutional Experience.
Article in Research and reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Testicular cancer (TC) is the leading cancer among adolescents and young adults (AYAs) aged 15-39 years and one of the most curable cancers. Objective: The study aims to assess epidemiology, histological classification, stage at diagnosis, prognosis, stage I risk assessment and relationship between prognosis and age in the Center of Chemotherapy and Radiotherapy at Latakia University Hospital. Methods: 318 patients with testicular cancer who had been attended to the Chemotherapy and Radiotherapy Center at Latakia University Hospital from its opening in 2007 until October 2025 were included in this retrospective analysis. Results: The median age at diagnosis was 32 years. The most prevalent testicular cancer (TC) was germ cell type. Among germ cell tumors, non-seminomatous types (51.6%) were slightly more frequent than seminomatous (45.9%). The most frequent non-seminomatous subtype was: mixed germ cell tumors (29.9%). The majority of TC patients were in stage I. About two-thirds of the seminoma patients were in stage I, while it represented about half of the non-seminoma patients with a significant difference between the two types. Two (2.86%) patients with vascular invasion, 31 (44.29%) with embryonal carcinoma, both vascular invasion and embryonal carcinoma in 8 (11.43%), and no risk factors were detected in 29 (41.43%) patients in non-seminoma. In seminoma, 40 (41.24%) patients reviewed with tumor size >4cm, 5 (5.15%) with rete testis invasion, 19 (19.59%) with both, and no risk factors were detected in 33 (34.02%) patients. No significant difference in the age of patients was shown after categorizing them according to their prognosis. Conclusion: The findings align with global proportions and can support those interested in the field in reducing disease burden, but further research is needed, especially in Syria and the Middle East due to limited studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.